These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 36294443)

  • 1. Guideline Directed Medical Therapy at Discharge and Further Uptitration Leading to Reduction in Indication for Prophylactic ICD Implantation during Protected Waiting Period.
    Waezsada E; Hutter J; Kahle P; Yogarajah J; Sperzel J; Kuniss M; Neumann T; Esser H; Hamm C; Hain A
    J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a guideline directed medical therapy titration program in patients with heart failure with reduced ejection fraction.
    Balakumaran K; Patil A; Marsh S; Ingrassia J; Kuo CL; Jacoby DL; Arora S; Soucier R
    Int J Cardiol Heart Vasc; 2019 Mar; 22():1-5. PubMed ID: 30480083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiology-A PROLONG-II Substudy.
    Mueller-Leisse J; Brunn J; Zormpas C; Hohmann S; Hillmann HAK; Eiringhaus J; Bauersachs J; Veltmann C; Duncker D
    Sensors (Basel); 2022 Mar; 22(5):. PubMed ID: 35271182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Playing it close to the VEST and the clinical guidelines: Clinical guideline compliance in HFrEF patients-Role of WCD.
    Mirro MJ; Keltner EE; Roebuck AE; Sears SF
    Pacing Clin Electrophysiol; 2018 Oct; 41(10):1314-1320. PubMed ID: 30091792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.
    Duncker D; König T; Hohmann S; Bauersachs J; Veltmann C
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).
    Kutyifa V; Moss AJ; Klein H; Biton Y; McNitt S; MacKecknie B; Zareba W; Goldenberg I
    Circulation; 2015 Oct; 132(17):1613-9. PubMed ID: 26316618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Heart Failure Optimization Study (HF-OPT): rationale and design.
    Sanchez R; Duncker D; Colley B; Doering M; Gummadi S; Perings C; Robertson M; Shroff G; Veltmann C;
    Herzschrittmacherther Elektrophysiol; 2023 Mar; 34(1):52-58. PubMed ID: 36695885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Resting Heart Rates Are Associated with Early Posthospitalization Mortality in Low Ejection Fraction Patients.
    Hain A; Busch N; Waezsada SE; Hutter J; Kahle P; Kuniss M; Neumann T; Masuda T; Esser HO; Hamm C; Sperzel J
    J Clin Med; 2022 May; 11(10):. PubMed ID: 35629031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avoiding implantation of a cardioverter-defibrillator by bridging with wearable defibrillator vest.
    Klein N; Kuntz T; Dhein S
    Herz; 2021 Mar; 46(2):172-177. PubMed ID: 31555894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Arrhythmic Risk Assessment Based on Ejection Fraction in Patients with Recent-Onset Nonischemic Dilated Cardiomyopathy.
    De Angelis G; Merlo M; Barbati G; Bertolo S; De Luca A; Ramani F; Adamo L; Sinagra G
    J Am Soc Echocardiogr; 2022 Aug; 35(8):801-809.e3. PubMed ID: 35367610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Guideline-Directed Medications for Heart Failure Before Cardioverter-Defibrillator Implantation.
    Roth GA; Poole JE; Zaha R; Zhou W; Skinner J; Morden NE
    J Am Coll Cardiol; 2016 Mar; 67(9):1062-1069. PubMed ID: 26940927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes during and after the use of the wearable cardioverter-defibrillator in a tertiary-care and a regional hospital in Switzerland.
    Kovacs B; Reek S; Saguner AM; Krasniqi N; Eriksson U; Duru F
    Swiss Med Wkly; 2019 Nov; 149():w20136. PubMed ID: 31707723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of wearable cardioverter-defibrillator use on long-term decision for implantation of a cardioverter-defibrillator in a semirural acute care hospital.
    Sinha AM; Bense J; Hohenforst-Schmidt W
    J Interv Card Electrophysiol; 2021 Nov; 62(2):401-407. PubMed ID: 33200285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Outcome of Patients Protected by the Wearable Cardioverter Defibrillator (WCD) for <90 Wear Days
    Dreher TC; El-Battrawy I; RÖger S; Rosenkaimer SL; Gerhards S; Kuschyk J; Borggrefe M; Akin I
    In Vivo; 2020; 34(6):3601-3610. PubMed ID: 33144474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of guideline-directed medical therapy among patients receiving cardiac resynchronization therapy defibrillator implantation in the National Cardiovascular Data Registry during the years 2006 to 2008.
    Schneider PM; Pellegrini CN; Wang Y; Fein AS; Reynolds MR; Curtis JP; Masoudi FA; Varosy PD
    Am J Cardiol; 2014 Jun; 113(12):2052-6. PubMed ID: 24793671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register.
    Pastore MC; Mandoli GE; Giannoni A; Benfari G; Dini FL; Pugliese NR; Taddei C; Correale M; Brunetti ND; Carluccio E; Mengoni A; Guaricci AI; Piscitelli L; Citro R; Ciccarelli M; Novo G; Corrado E; Pasquini A; Loria V; Degiovanni A; Patti G; Santoro C; Moderato L; Malagoli A; Emdin M; Cameli M; ; Rosa G; Magnesa M; Mazzeo P; De Carli G; Bellino M; Iuliano G; Casciano O; Binno S; Canepa M; Tondi S; Cicoira M; Mega S
    Eur Heart J Open; 2022 Jan; 2(1):oeab046. PubMed ID: 35919657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up.
    Paolini C; Mugnai G; Dalla Valle C; Volpiana A; Ferraglia A; Frigo AC; Bilato C
    Int J Cardiol Heart Vasc; 2021 Aug; 35():100821. PubMed ID: 34179333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the Wearable Cardioverter-Defibrillator Among Patients With Myocarditis and Reduced Ejection Fraction or Ventricular Tachyarrhythmia: Data From a Multicenter Registry.
    El-Battrawy I; Koepsel K; Tenbrink D; Kovacs B; Dreher TC; Blockhaus C; Gotzmann M; Klein N; Kuntz T; Shin DI; Lapp H; Rosenkaimer S; Abumayyaleh M; Hamdani N; Saguner AM; Kowitz J; Erath JW; Duru F; Mügge A; Akin I; Aweimer A; Beiert T
    J Am Heart Assoc; 2023 Sep; 12(18):e030615. PubMed ID: 37681569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66).
    Foo FS; Lee M; Poppe KK; Clare GC; Stiles MK; Gavin A; Webber M; Jackson R; Kerr AJ
    Heart Lung Circ; 2022 Nov; 31(11):1531-1538. PubMed ID: 35999128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.